Five-Year Survival Rate for Myelodysplastic Syndrome
The 5-year survival rate for MDS varies dramatically by risk category, ranging from approximately 18% to 68% depending on disease subtype and risk stratification, with an overall population-based 5-year survival of approximately 31-37%.
Overall Population Survival
The overall 5-year survival rate for all MDS patients combined is approximately 31-37% 1, 2. However, this aggregate number masks the profound heterogeneity of MDS and should not be used for individual patient counseling without proper risk stratification.
Risk-Stratified Survival Rates
The survival in MDS is highly dependent on risk category according to the International Prognostic Scoring System-Revised (IPSS-R), which is the gold standard for prognostication 3:
IPSS-R Risk Categories (Median Overall Survival):
- Very Low Risk: 90 months (7.5 years) 3
- Low Risk: 54 months (4.5 years) 3
- Intermediate Risk: 34 months (2.8 years) 3
- High Risk: 21 months (1.75 years) 3
- Very High Risk: 13 months (1.1 years) 3
Converting these median survival times to approximate 5-year survival rates: patients with very low and low-risk disease have substantially better than 50% 5-year survival, while intermediate-risk patients have approximately 30-40% 5-year survival, and high/very high-risk patients have less than 20% 5-year survival.
WHO Subtype-Specific Survival
According to WHO classification subtypes, 5-year relative survival rates are 4:
- Refractory Anemia (RA): 53%
- RA with Ringed Sideroblasts: 58%
- 5q-syndrome: 48%
- Refractory Cytopenia with Multilineage Dysplasia: 38%
- RA with Excess Blasts: 18%
Key Prognostic Factors Affecting Survival
Beyond risk scores, several factors significantly impact survival 5:
- Age: Median age at diagnosis is 70 years; older patients have worse outcomes 1
- Cytogenetics: Unfavorable karyotypes dramatically worsen prognosis
- Transfusion dependence: Associated with worse outcomes
- Bone marrow blast percentage: Higher percentages correlate with shorter survival
- Specific mutations: ASXL1, TP53, DNMT3A mutations associated with worse prognosis 6
Lower-Risk vs Higher-Risk Disease
For clinical decision-making, MDS is typically divided into two broad categories 5:
- Lower-risk MDS (IPSS low and intermediate-1): Median survival 3-10 years; approximately half of elderly patients die from causes unrelated to MDS 5, 1
- Higher-risk MDS (IPSS intermediate-2 and high): Median survival less than 3 years 1
Important Clinical Caveats
The overall 5-year survival has NOT improved significantly over time despite approval of new therapies since 2004 2, 4. This sobering reality reflects:
- The advanced age of most patients at diagnosis
- Limited availability and uptake of disease-modifying therapies
- The fact that most patients (89%) receive only supportive care 4
Bone marrow failure (infection and hemorrhage) is the leading cause of death, with more patients dying before overt AML transformation occurs 5. The risk of AML progression at 5 years is 25-35% 5.
Treatment Impact on Survival
Allogeneic stem cell transplantation remains the only potentially curative option and can achieve 40-60% disease-free survival at 5 years in appropriate candidates 7, 8, but most patients are too elderly or have excessive comorbidities for this approach 5, 8.